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ABSTRACT 
Whether there is an increased risk of occurrence of neuroleptic malignant syndrome (NMS) 
on combined treatment with lithium and neuroleptic is a controversial issue. Patients seen in a 
general psychiatry unit of a university hospital in India were prospectively screened for NMS over 
a 2 year period. Diagnosis of NMS was made on operational criteria and the details of treatment at 
the time of occurrence of NMS were collected systematically. Eight cases of NMS were identified 
during the period of the study, out of which 5 (62.5%). were taking lithium and a neuroleptic to-
gether at the time of occurrence of NMS. The high prevalence of patients on lithium and 
neuroleptic concomitantly in our sample of NMS, and the similar findings in many of the earlier 
prospective studies, makes it possible to speculate whether there is an association between com-
bined use of lithium and neuroleptic and occurrence of NMS. Findings are discussed. 
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Neuroleptic malignant syndrome (NMS) 
is a rare but potentially lethal condition, 
estimated to occur in 0.02% to 3.23% of pa-
tients treated with neuroleptics (Addonizio & 
Susman, 1991; Carrof & Mann, 1993). Though 
a variety of risk factors like use of high 
potency neuroleptics, rapid dose escalation, 
administration of parenteral neuroleptics, use 
of high dose of neuroleptics, organic brain 
disorder, affective disorder, agitation etc. have 
been reported to increase the risk of NMS, 
consensus about aetiopathogenesis is elusive 
(Levenson, 1985; Addonizio & Susman,'1991; 
Carroff & Mann, 1993;). 
The role of lithium (when used concur-
rently with neuroleptic) in increasing the risk of 
NMS is a controversial issue. There are many 
case reports of increased neurotoxicity and 
NMS occurring with a combination of lithium 
and neuroleptics, especially with haloperidol 
(Cohen & Cohen, 1974; Loudon & Waring, 1976; 
Spring & Frankel, 1991). Retrospective 
analysis have found that upto 50% of patients 
who developed NMS were on treatment with 
lithium and neuroleptics at the time of 
occurrence of NMS (Addibuzui et al., 1986; 
Kecketal., 1989). Also, Kecketal. (1987) and 
Rosebush & Stewart (1988) found on 
prospective studies that 50% or more of 
patients with NMS w,ere taking lithium along 
with a neuroleptic when they developed NMS. 
These authors found that NMS can occur when 
lithium is used with neuroleptics other than ha-
loperidol also. However, some retrospective 
studies didn't find any evidence of neurotoxic-
ity with concurrent use of lithium and neurolep-
tics (Baastrup et al., 1976; Goldney & Spence, 
1986). A variety of methodological factors like 
the retrospective design, imprecise diagnosis 
of NMS, non-control of other variables etc. could 
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have confounded the results of many studies. 
In Indian literature there is a paucity of 
reports on NMS (Thomas et al., 1993). 
Epidemiological studies from various countries 
have shown that bipolar disorder has an esti-
mated life time risk of around 1% (Goodwin & 
Jamison, 1990). In view of the large population 
of India and enormous number of patients ex-
posed to this treatment combination of litium 
and neuroleptic/s, we conducted a prospective 
study about the association of combined us'e of 
lithium and neuroleptic and the occurrence of 
NMS. 
MATERIAL & METHOD 
All the cases seen at psychiatry unit of 
Kasturba Hospital, Manipal from January 1994 
to December 1995 were carefully assessed for 
NMS. This psychiatry unit runs its outpatient 
clinic three times a week and on these days 
besides outdoor patients attending the section, 
the unit also saw all the inpatient referrals from 
other departments and the emergency calls. 
This is a referral hospital, catering to a geo-
graphical area of two southern states of India. 
The present report is a part of study to assess 
the prevalence and risk factors for NMS. 
The diagnosis of NMS was made when 
patients exposed in the past 1 week to neurolep-
tic (4 weeks in case of depot neuroleptic prepa-
ration) had fever, rigidity, altered consciousness 
and autonomic instability which couldn't be 
accounted by any other physical or mental ill-
ness (Carroff et al., 1991). All the patients were 
also seen by a consultant neurologist and ap-
propriate investigations to rule out neurological 
illness to account for these symptoms were 
done. When clinically indicated, patients were 
referred to other consultants and relevant 
investigations tc rule out other physical disor-
ders were carried out. Details of the drug treat-
ment was collected from the close relative/s, 
available prescriptions at the time of admission 
and from the patients after they recovered from 
the episode of NMS. Informed consent was 
obtained from all the patients for the use of 
clinical records. 
RESULTS 
Eight cases who met the operational 
criteria of NMS were identified. The age, sex, 
ICD-10 psychiatric diagnosis (WHO, 1992) and 
details of drug treatment of the 8 patients are 
shown in table . The age range of the patients 
was from 21 to 63 years. Male and female were 
equally present in the sample. Seven (87.5%) 
of the patients were suffering from affective 
disorder. Except one all the other patients were 
on treatment from practising psychiatrists or 
other doctors. A diagnosis of NMS as a 
possibility was mentioned in only 2 of the 
referrals by the treating doctor. 
Out of the 8 patients, 5 were taking 
lithium and a neuroleptic concomitantly when 
they developed NMS. Serum lithium level was 
within the therapeutic range in all the 5 patients 
on lithium (range being 0.4 milliequivalents to 
1.2 milliequivalents) which was done at 
varying points of time (24 hours to 72 hours 
after the last dose of lithium). 
DISCUSSION 
Our diagnosis of NMS was made on 
operational criteria of Caroff et al. (1991) and 
also met the research criteria proposed by 
DSM-IV (APA, 1994). We have tried to exclude 
by careful evaluation other systemic and neu-
ropsychiatric illnesses producing the symptoms 
of NMS. It has been observed that NMS be over 
diagnosed if broad criteria are applied as other 
medical causes may account for the symptoms 
necessary for the diagnoses of NMS (Levinson 
& Simpson, 1986). 
It may be difficult in some cases to dis-
tinguish between lithium neurotoxicity and NMS, 
since lithium in therapeutic range is known to 
produce neurotoxicity (Schou, 1984). In some 
patients there can be features of both lithium 
toxicity and NMS (Cohen & Cohen, 1984). How-
ever, lithium toxicity is not usually associated 
with fever and typically its neurotoxicity 
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manifests with weakness, extreme lethargy, cer-
ebellar signs, fasciculations, myoclonic jerKS 
and seizure (Schou, 1984; Sansone & Zeigler, 
1985; Rosebush & Stewart, 1989). Thus, based 
on the symptomatology, in most cases it is pos-
sible to distinguish lithium toxicity and NMS. It 
is unlikely that any of our patient primarily had 
lithium toxicity. 
The findings of the present study is in 
concordance with observations in literature that 
a majority of patients who develop NMS are on 
haloperidol. However, this may reflect prescrib-
ing practice rather than any specific risk for 
haloperidol (Addonizio & Susman, 1991). 
Lithium in combination with other neuroleptics 
is also known to produce NMS (Addonizio & 
Susman, 1991; Carroff & Mann, 1993). 
Keck et al. (1987) found 6 cases of NMS, 
3 were on lithium and neuroleptic. The authors 
opined that lithium might have increased the 
frequency of NMS. Similarly, Rosebush et al. 
(1989) in their study found that lithium was 
being used in 58% of those who developed 
NMS, enabling them to raise the question of an 
association between concomitant lithium and 
neuroleptic use and development of NMS. 
These findings make it possible to speculate 
that there is an increased risk of occurrence of 
NMS when patients are treated with a combi-
nation of lithium and antipsychotic/s. 
A variety of ways of which lithium can 
increase the risk of development of NMS have 
been proposed (Rosebush et al., 1989; Ad-
donizio & Susman, 1991). Lithium alone can 
cause extrapyramidal (EPS) symptoms 
(Shopsin & Gershon, 1975) and it is known that 
it enhances the EPS produced by neuroleptics 
(Addonizio, 1985). It may also increase the 
TABLE 
CHARACTERISTICS OF PATIENTS WITH NEUROLEPTC MALIGNANT SYNDROME 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
Age 
30 
21 
24 
62 
55 
63 
22 
26 
Sex 
F 
M 
M 
M 
M 
F 
F 
F 
Psychiatric Diagnosis 
Unspecified nonorganic 
psychosis (postpartum) 
BAD. Currently Mania 
B.A.D. Currently Mania 
B.A.D. Currently Mania 
B.A.D. Currently Mania 
B.A.D. Currently Mania 
Severe Depressive Episode 
(postpartum) 
Severe Depressive Episode 
(postpartum) 
Medications Per Day 
Chlorpromazine - 20mg 
Lithium 900 mg+ 
Thioridazine 100 mg 
Lithium 900 mg+ 
Haloperidol 15 mg 
Lithium 600 mg + 
Haloperidol 5mg+ 
Carbamazepine 600 mg 
Lithium 600 mg + 
Haloperidol 20 mg 
Lithium 900mg + 
Haloperidol 50mg 
Amoxa pine 100 mg 
Trifluperazine 20mg + 
Chlopromazine 100 mg+ 
Trihexyphenidyl 4 mg 
B.A.D. Bipolar Affective Disorder 
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chance of a hypodopaminergic state and this is 
implicated in the pathogenesis of NMS (Ad-
donizio &Susman, 1991). Also, these drugs by 
interaction may alter intercellular and serum 
levels of both the drugs thereby increasing the 
risk of NMS. Lithium toxicity can predispose to 
the development of NMS by electrolyte 
imbalance and renal dysfunction. Even in 
nontoxic range lithium by inducing polyuria, can 
produce fluid and electrolyte imbalance and 
increase the risk for NMS (Addonizio & 
Susman, 1991; Carroff & Mann, 1993). 
Alternatively, it can be conceptualised 
that lithium is likely to be used in 
affective disorder and since these patients are 
likely to get agitated and excited, all these fac-
tors are proposed risks for NMS, the associa-
tion between lithium and NMS may be spuri-
ous. Retrospective studies have found that there 
are significantly more patients with affective 
disorders in NMS than in controls (Addonizio et 
al., 1986; Keck etal., 1989). In the present study 
also, 87.5% of patients were of affective 
disorder. 
However, it can't be concluded definitely 
from our study that lithium neuroleptic 
combination increases the risk of NMS. In 
clinical practice these drugs are often used in 
combination with no untoward effects. Two 
retrospective studies (Baastrup et al., 1976; 
Goldney & Spence, 1986) found no significant 
risk of neurotoxicity or NMS with this 
combination. Similarly, retrospective studies for 
risk factors of NMS using control groups have 
found no significantly increased use of lithium 
in NMS patients compared to controls who didnt 
develop NMS (Addonizio et al., 1986; Keck et 
al., 1989). Deng et al. (1990) in a prospective 
study of 7 years identified 12 cases of NMS 
and found that only 1 was on lithium and thus 
concluded that lithium is not a significant risk 
factor for NMS. 
The confounding effects of risk factor for 
NMS need study using multivariate statistical 
techniques. Unless large sample size are 
collected using collaborative effort from 
multiple centres, it may be difficult to precisely 
pin point the risk factors for NMS, including that 
of lithium. 
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